RU2005123328A - Оксазолы в качестве усилителей mgiuri - Google Patents
Оксазолы в качестве усилителей mgiuri Download PDFInfo
- Publication number
- RU2005123328A RU2005123328A RU2005123328/04A RU2005123328A RU2005123328A RU 2005123328 A RU2005123328 A RU 2005123328A RU 2005123328/04 A RU2005123328/04 A RU 2005123328/04A RU 2005123328 A RU2005123328 A RU 2005123328A RU 2005123328 A RU2005123328 A RU 2005123328A
- Authority
- RU
- Russia
- Prior art keywords
- trifluoromethyloxazol
- xanthene
- carboxylic acid
- acid amide
- formula
- Prior art date
Links
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- -1 4-trifluoromethyloxazol-2-yl Chemical group 0.000 claims 2
- WEDLKOCAEPRSPJ-UHFFFAOYSA-N 9h-xanthene-9-carboxamide Chemical compound C1=CC=C2C(C(=O)N)C3=CC=CC=C3OC2=C1 WEDLKOCAEPRSPJ-UHFFFAOYSA-N 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- UDEUSZJCYDZNRS-UHFFFAOYSA-N 4-chloro-n-[4-(trifluoromethyl)-1,3-oxazol-2-yl]-9h-xanthene-9-carboxamide Chemical compound FC(F)(F)C1=COC(NC(=O)C2C3=CC=CC(Cl)=C3OC3=CC=CC=C32)=N1 UDEUSZJCYDZNRS-UHFFFAOYSA-N 0.000 claims 1
- LPLUZKBFQYNESD-UHFFFAOYSA-N 4-fluoro-n-[4-(trifluoromethyl)-1,3-oxazol-2-yl]-9h-xanthene-9-carboxamide Chemical compound C12=CC=CC=C2OC=2C(F)=CC=CC=2C1C(=O)NC1=NC(C(F)(F)F)=CO1 LPLUZKBFQYNESD-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- CURYKKYYXNNUPL-UHFFFAOYSA-N FC(C=1N=C(OC1)C1=CC(=CC=2OC3=CC=CC=C3C(C12)C(=O)N)F)(F)F Chemical compound FC(C=1N=C(OC1)C1=CC(=CC=2OC3=CC=CC=C3C(C12)C(=O)N)F)(F)F CURYKKYYXNNUPL-UHFFFAOYSA-N 0.000 claims 1
- SIGILZPDRXGOMJ-UHFFFAOYSA-N NC(C(C1=C2)C(C(C3=NC(C(F)(F)F)=CO3)=C(C=C3)F)=C3OC1=CC=C2F)=O Chemical compound NC(C(C1=C2)C(C(C3=NC(C(F)(F)F)=CO3)=C(C=C3)F)=C3OC1=CC=C2F)=O SIGILZPDRXGOMJ-UHFFFAOYSA-N 0.000 claims 1
- BKWRBZHXTQERGJ-UHFFFAOYSA-N NC(C(C1=C2)C(C(C3=NC=C(C(F)(F)F)O3)=C(C=C3)F)=C3OC1=CC=C2F)=O Chemical compound NC(C(C1=C2)C(C(C3=NC=C(C(F)(F)F)O3)=C(C=C3)F)=C3OC1=CC=C2F)=O BKWRBZHXTQERGJ-UHFFFAOYSA-N 0.000 claims 1
- OPLCBXYSDAZWPN-UHFFFAOYSA-N NC(C1C(C(C2=NC(C(F)(F)F)=CO2)=C(C=C2)Cl)=C2OC2=CC=CC=C12)=O Chemical compound NC(C1C(C(C2=NC(C(F)(F)F)=CO2)=C(C=C2)Cl)=C2OC2=CC=CC=C12)=O OPLCBXYSDAZWPN-UHFFFAOYSA-N 0.000 claims 1
- TYZXBPIBUFSUND-UHFFFAOYSA-N NC(C1C(C(C2=NC(C(F)(F)F)=CO2)=C(C=C2)F)=C2OC2=CC=CC=C12)=O Chemical compound NC(C1C(C(C2=NC(C(F)(F)F)=CO2)=C(C=C2)F)=C2OC2=CC=CC=C12)=O TYZXBPIBUFSUND-UHFFFAOYSA-N 0.000 claims 1
- QUALENVTKZPMPJ-UHFFFAOYSA-N NC(C1C(C(C2=NC(C(F)(F)F)=CO2)=CC(F)=C2)=C2OC2=CC(F)=CC=C12)=O Chemical compound NC(C1C(C(C2=NC(C(F)(F)F)=CO2)=CC(F)=C2)=C2OC2=CC(F)=CC=C12)=O QUALENVTKZPMPJ-UHFFFAOYSA-N 0.000 claims 1
- YBGQBVROBIAEIF-UHFFFAOYSA-N NC(C1C(C(C2=NC=C(C(F)(F)F)O2)=C(C=C2)F)=C2OC2=CC=CC=C12)=O Chemical compound NC(C1C(C(C2=NC=C(C(F)(F)F)O2)=C(C=C2)F)=C2OC2=CC=CC=C12)=O YBGQBVROBIAEIF-UHFFFAOYSA-N 0.000 claims 1
- NFQIWHVNCKMJIO-UHFFFAOYSA-N NC(C1C(C(C2=NC=C(C(F)(F)F)O2)=CC(F)=C2)=C2OC2=CC(F)=CC=C12)=O Chemical compound NC(C1C(C(C2=NC=C(C(F)(F)F)O2)=CC(F)=C2)=C2OC2=CC(F)=CC=C12)=O NFQIWHVNCKMJIO-UHFFFAOYSA-N 0.000 claims 1
- RACYAQSARGIDQI-UHFFFAOYSA-N NC(C1C(C(C2=NC=C(C(F)(F)F)O2)=CC(F)=C2)=C2OC2=CC=CC=C12)=O Chemical compound NC(C1C(C(C2=NC=C(C(F)(F)F)O2)=CC(F)=C2)=C2OC2=CC=CC=C12)=O RACYAQSARGIDQI-UHFFFAOYSA-N 0.000 claims 1
- HBBCDOZBJPAMTC-UHFFFAOYSA-N NC(C1C(C(C2=NC=C(C(F)(F)F)O2)=CC=C2F)=C2OC2=CC=CC=C12)=O Chemical compound NC(C1C(C(C2=NC=C(C(F)(F)F)O2)=CC=C2F)=C2OC2=CC=CC=C12)=O HBBCDOZBJPAMTC-UHFFFAOYSA-N 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (8)
1. Соединение общей формулы I
где один из R1 и R2 означает трифторметил, а другой означает водород;
R3, R3' независимо друг от друга означают водород или галоген,
а также его фармацевтически приемлемые соли.
2. Соединения формулы I по п.1, которые выбирают из следующих соединений:
(4-трифторметилоксазол-2-ил)амид 9Н-ксантен-9-карбоновой кислоты,
(5-трифторметилоксазол-2-ил)амид 9Н-ксантен-9-карбоновой кислоты,
(5-трифторметилоксазол-2-ил)амид 2-фтор-9Н-ксантен-9-карбоновой кислоты,
(5-трифторметилоксазол-2-ил)амид 3-фтор-9Н-ксантен-9-карбоновой кислоты,
(5-трифторметилоксазол-2-ил)амид 4-фтор-9Н-ксантен-9-карбоновой кислоты,
(5-трифторметилоксазол-2-ил)амид 2,7-дифтор-9Н-ксантен-9-карбоновой кислоты и
(5-трифторметилоксазол-2-ил)амид 3,6-дифтор-9Н-ксантен-9-карбоновой кислоты,
(4-трифторметилоксазол-2-ил)амид 2-фтор-9Н-ксантен-9-карбоновой кислоты,
(4-трифторметилоксазол-2-ил)амид 3-фтор-9Н-ксантен-9-карбоновой кислоты,
(4-трифторметилоксазол-2-ил)амид 4-фтор-9Н-ксантен-9-карбоновой кислоты,
(4-трифторметилоксазол-2-ил)амид 2,7-дифтор-9Н-ксантен-9-карбоновой кислоты,
(4-трифторметилоксазол-2-ил)амид 3,6-дифтор-9Н-ксантен-9-карбоновой кислоты,
(4-трифторметилоксазол-2-ил)амид 2-хлор-9Н-ксантен-9-карбоновой кислоты и
(4-трифторметилоксазол-2-ил)амид 4-хлор-9Н-ксантен-9-карбоновой кислоты.
3. Способ получения соединения формулы I по п.1 и его фармацевтически приемлемых солей, который включает взаимодействие соединения формулы II
где один из R1 и R2 означает трифторметил, а другой означает водород, с соединением формулы III
где R3, R3' независимо друг от друга означают водород или галоген, a G означает хлор или гидрокси,
и необязательно превращение полученного соединения формулы I в фармацевтически приемлемую соль.
4. Соединение формулы I, полученное способом по п.3.
5. Соединение формулы I по п.1 для лечения и профилактики заболеваний.
6. Применение соединения формулы I по п.1 для получения лекарственного средства, предназначенного для лечения и профилактики заболеваний, ассоциированных с рецептором mGlu 1.
7. Лекарственное средство, содержащее соединение формулы I по п.1 и фармацевтически приемлемые эксципиенты.
8. Лекарственное средство по п.7, предназначенное для лечения и профилактики заболеваний, ассоциированных с рецептором mGlu 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02028747.0 | 2002-12-23 | ||
| EP02028747 | 2002-12-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005123328A true RU2005123328A (ru) | 2006-02-27 |
| RU2345076C2 RU2345076C2 (ru) | 2009-01-27 |
Family
ID=32668736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005123328/04A RU2345076C2 (ru) | 2002-12-23 | 2003-12-17 | ОКСАЗОЛЫ В КАЧЕСТВЕ УСИЛИТЕЛЕЙ mGluR1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7119113B2 (ru) |
| EP (1) | EP1578746B1 (ru) |
| JP (1) | JP4286788B2 (ru) |
| KR (1) | KR100713265B1 (ru) |
| CN (1) | CN100336813C (ru) |
| AR (1) | AR042643A1 (ru) |
| AT (1) | ATE329913T1 (ru) |
| AU (1) | AU2003298195B8 (ru) |
| BR (1) | BR0317714A (ru) |
| CA (1) | CA2511337C (ru) |
| DE (1) | DE60306202T2 (ru) |
| ES (1) | ES2265600T3 (ru) |
| MX (1) | MXPA05006657A (ru) |
| PL (1) | PL211061B1 (ru) |
| RU (1) | RU2345076C2 (ru) |
| WO (1) | WO2004056814A1 (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2534529A1 (en) * | 2003-08-06 | 2005-02-24 | Pfizer Products Inc. | Oxazole compounds for the treatment of neurodegenerative disorders |
| TW200732313A (en) | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| WO2009098455A1 (en) * | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease |
| CN103319447B (zh) * | 2013-06-18 | 2015-05-20 | 烟台万润精细化工股份有限公司 | 一种呫吨-9-羧酸的制备方法 |
| US12156879B2 (en) * | 2019-12-02 | 2024-12-03 | University Of Connecticut | Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2629752A1 (de) * | 1976-07-02 | 1978-01-05 | Boehringer Mannheim Gmbh | Neue carbonsaeurederivate und verfahren zu ihrer herstellung |
| US6803381B1 (en) * | 1999-04-20 | 2004-10-12 | Hoffmann-La Roche Inc. | Carbamic acid derivatives |
| TW593241B (en) * | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
-
2003
- 2003-12-17 PL PL377708A patent/PL211061B1/pl unknown
- 2003-12-17 AU AU2003298195A patent/AU2003298195B8/en not_active Ceased
- 2003-12-17 ES ES03795907T patent/ES2265600T3/es not_active Expired - Lifetime
- 2003-12-17 DE DE60306202T patent/DE60306202T2/de not_active Expired - Lifetime
- 2003-12-17 RU RU2005123328/04A patent/RU2345076C2/ru not_active IP Right Cessation
- 2003-12-17 MX MXPA05006657A patent/MXPA05006657A/es active IP Right Grant
- 2003-12-17 CN CNB2003801072986A patent/CN100336813C/zh not_active Expired - Fee Related
- 2003-12-17 AT AT03795907T patent/ATE329913T1/de active
- 2003-12-17 EP EP03795907A patent/EP1578746B1/en not_active Expired - Lifetime
- 2003-12-17 BR BR0317714-9A patent/BR0317714A/pt not_active IP Right Cessation
- 2003-12-17 KR KR1020057011724A patent/KR100713265B1/ko not_active Expired - Fee Related
- 2003-12-17 WO PCT/EP2003/014395 patent/WO2004056814A1/en not_active Ceased
- 2003-12-17 JP JP2004561328A patent/JP4286788B2/ja not_active Expired - Fee Related
- 2003-12-17 CA CA2511337A patent/CA2511337C/en not_active Expired - Fee Related
- 2003-12-18 US US10/740,245 patent/US7119113B2/en not_active Expired - Fee Related
- 2003-12-22 AR ARP030104765A patent/AR042643A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1578746B1 (en) | 2006-06-14 |
| US7119113B2 (en) | 2006-10-10 |
| AU2003298195B2 (en) | 2009-04-02 |
| EP1578746A1 (en) | 2005-09-28 |
| JP2006512343A (ja) | 2006-04-13 |
| US20040132792A1 (en) | 2004-07-08 |
| PL377708A1 (pl) | 2006-02-06 |
| JP4286788B2 (ja) | 2009-07-01 |
| DE60306202D1 (de) | 2006-07-27 |
| KR100713265B1 (ko) | 2007-05-04 |
| DE60306202T2 (de) | 2007-06-06 |
| AU2003298195A1 (en) | 2004-07-14 |
| ATE329913T1 (de) | 2006-07-15 |
| MXPA05006657A (es) | 2005-08-16 |
| AU2003298195B8 (en) | 2009-04-23 |
| CA2511337A1 (en) | 2004-07-08 |
| CN100336813C (zh) | 2007-09-12 |
| BR0317714A (pt) | 2005-11-22 |
| PL211061B1 (pl) | 2012-04-30 |
| WO2004056814A1 (en) | 2004-07-08 |
| RU2345076C2 (ru) | 2009-01-27 |
| CN1735610A (zh) | 2006-02-15 |
| KR20050087848A (ko) | 2005-08-31 |
| AR042643A1 (es) | 2005-06-29 |
| ES2265600T3 (es) | 2007-02-16 |
| CA2511337C (en) | 2011-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
| JP2003532731A5 (ru) | ||
| EA200500164A1 (ru) | N-арилдиазаспирациклические соединения и способы их получения и применения | |
| HRP20090281T1 (hr) | 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti | |
| CY1108292T1 (el) | Αντικαρκινικο σκευασμα που περιεχει dmxaa | |
| UA100132C2 (en) | Isoxazolo-pyridine derivatives | |
| JP2007501809A5 (ru) | ||
| EA200400881A1 (ru) | Азаарилпиперазины | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| EA200401114A2 (ru) | Замещённые гидроксиэтиламины | |
| EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
| CY1107753T1 (el) | 2,5-δισυποκατεστημενο 3-μερκαπτοπεντανοϊκο οξυ | |
| RU2008139195A (ru) | Замещенные арилсульфанамиды как противовирусные средства | |
| CY1110450T1 (el) | Χρησιμοποιηση ενος παραγωγου αλογονιδιου υδροξιμικου οξεος στη θεραπευτικη αγωγη νευροεκφυλιστικων νοσων | |
| EA200301276A1 (ru) | Новые производные сульфоновых кислот | |
| RU2005121908A (ru) | Производные зн-хиназолин-4-она | |
| EA201270266A1 (ru) | Гетероциклические соединения | |
| DK1228758T3 (da) | Anvendelse af sulfodehydroabietinsyre til behandling af inflammatorisk tarmsygdom | |
| EA200602016A1 (ru) | ПОРОШКОВЫЕ КОМПОЗИЦИИ ДЛЯ ИНГАЛЯЦИИ, СОДЕРЖАЩИЕ ЭНАНТИОМЕРНОЧИСТЫЕ β-АГОНИСТЫ | |
| EA018079B1 (ru) | Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона | |
| RU2005123328A (ru) | Оксазолы в качестве усилителей mgiuri | |
| RU2002121636A (ru) | Производные индола в качестве антагонистов рецепторов мср-1 | |
| EP1201240A3 (en) | Heterocyclic derivatives useful as pharmaceutical agents | |
| RU2011111117A (ru) | Лечение аутоиммунных заболеваний | |
| RU2010151143A (ru) | Замещенные хиназолины |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20181218 |